Aidea Pharma(SH:688488)2025-01-17 10:10Revenue Expectations - The company expects a total operating revenue of approximately 419.27 million yuan for 2024, an increase of about 7.90 million yuan or 1.92% compared to the previous year [3]. Profit Projections - The projected net profit attributable to the parent company is expected to be between -95 million yuan and -142.5 million yuan, a decrease of approximately 18.93 million yuan to 66.43 million yuan, representing a decline of about 24.89% to 87.33% year-on-year [3]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -119.4 million yuan and -179.1 million yuan, a decrease of approximately 31.34 million yuan to 91.04 million yuan, indicating a decline of about 35.59% to 103.38% year-on-year [3]. Business Performance - The gross profit from the main business increased by approximately 38 million yuan compared to the same period last year [6]. - Sales expenses increased by approximately 51 million yuan due to intensified promotion of new drugs [6]. - Research and development expenses increased by approximately 27 million yuan as the company further increased its R&D investment [6]. Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant [7]. - The company has not identified any significant uncertainties that could affect the accuracy of this performance forecast [7]. - The forecast data is preliminary and the specific accurate financial data will be disclosed in the audited annual report for 2024 [8]. - Investors are advised to pay attention to investment risks related to the preliminary nature of the forecast data [8].